We are analyzing https://link.springer.com/article/10.1007/s10549-016-4080-9.

Title:
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed | Breast Cancer Research and Treatment
Description:
We hypothesized different Overall Survival (OS) in metastatic breast cancer (MBC) after relapse vs de novo presentation. We identified women in British Columbia with MBC diagnosed between 01/2001 and 12/2009. OS from MBC was calculated for relapsed vs de novo cohorts in 3 subgroups, based on hormone receptors (HR) and HER2 status. Age at MBC, disease-free interval (DFI), de novo vs relapsed, year of MBC diagnosis, and systemic treatment were entered into univariable and multivariable analyses. We identified 3645 pts with known HR of which 2796 had known HER2. Median follow-up was 91 months. Median OS was longer for de novo vs relapsed MBC: HR+/HER2- 34 versus 23 months (mos) (p < 0.0001), HR−/HER2- (TN) 11 versus 8 mos (p = 0.02), HER2+ 29 versus 15 mos (p < 0.0001). For TN disease, no variable independently discriminated a group with increased risk of death. For both the HR +/HER2- and the HER2 + groups, relapsed vs de novo status (HzR 1.4 [95% CI 1.2–1.5; p < 0.0001], and HzR 1.6 [95% CI 1.4–1.9; p < 0.0001], respectively) and age >50 (HzR 1.2 [95% CI 1.1–1.4; p = 0.001] and HzR 1.3 [95% CI 1.1–1.5; p = 0.01], respectively) were associated with increased risk of death on multivariable analysis. These data provide information that may guide discussions about prognosis between physicians and patients with MBC. In addition, it highlights the importance of stratifying for initial stage at diagnosis in future MBC therapeutic trials.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

cancer, breast, article, google, scholar, pubmed, metastatic, cas, novo, survival, clin, data, relapsed, mbc, treatment, patients, research, versus, access, nature, central, herpositive, privacy, cookies, content, trials, clinical, chemotherapy, oncol, med, analysis, information, publish, search, presentation, december, brok, caroline, speers, disease, hzr, recurrent, patterns, study, res, evolution, engl, author, authors, log,

Topics {✒️}

month download article/chapter triple-negative breast cancer her2-positive de novo lymph node-negative disease early breast cancer cancer staging system metastatic breast cancer disease-free interval relapsed breast cancer breast cancer subtypes related subjects de novo cohorts full article pdf privacy choices/manage cookies breast carcinoma survival de novo status de novo presentation human breast tumours ethics declarations conflict bc cancer agency breast cancer author information authors prospective study evaluating european economic area variable independently discriminated comprehensive molecular portraits american joint committee single nucleotide resolution van kampen rjw anonymized electronic records metastatic disease branched evolution revealed conditions privacy policy de novo long-term follow electronic supplementary material her2-positive clonal genome evolution mutational evolution spectrum accepting optional cookies consultant/advisory role article log hormonal therapy accepted received https journal finder publish author correspondence published data provide information

Questions {❓}

Chia S (2012) Testing for discordance at metastatic relapse: does it matter?
Lebbezoo DJA, van Kampen RJW et al (2015) Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
         description:We hypothesized different Overall Survival (OS) in metastatic breast cancer (MBC) after relapse vs de novo presentation. We identified women in British Columbia with MBC diagnosed between 01/2001 and 12/2009. OS from MBC was calculated for relapsed vs de novo cohorts in 3 subgroups, based on hormone receptors (HR) and HER2 status. Age at MBC, disease-free interval (DFI), de novo vs relapsed, year of MBC diagnosis, and systemic treatment were entered into univariable and multivariable analyses. We identified 3645 pts with known HR of which 2796 had known HER2. Median follow-up was 91 months. Median OS was longer for de novo vs relapsed MBC: HR+/HER2- 34 versus 23 months (mos) (p < 0.0001), HR−/HER2- (TN) 11 versus 8 mos (p = 0.02), HER2+ 29 versus 15 mos (p < 0.0001). For TN disease, no variable independently discriminated a group with increased risk of death. For both the HR +/HER2- and the HER2 + groups, relapsed vs de novo status (HzR 1.4 [95% CI 1.2–1.5; p < 0.0001], and HzR 1.6 [95% CI 1.4–1.9; p < 0.0001], respectively) and age >50 (HzR 1.2 [95% CI 1.1–1.4; p = 0.001] and HzR 1.3 [95% CI 1.1–1.5; p = 0.01], respectively) were associated with increased risk of death on multivariable analysis. These data provide information that may guide discussions about prognosis between physicians and patients with MBC. In addition, it highlights the importance of stratifying for initial stage at diagnosis in future MBC therapeutic trials.
         datePublished:2016-12-20T00:00:00Z
         dateModified:2016-12-20T00:00:00Z
         pageStart:549
         pageEnd:556
         sameAs:https://doi.org/10.1007/s10549-016-4080-9
         keywords:
            Relapsed metastatic breast cancer
            De novo metastatic breast cancer
            Overall survival metastatic breast cancer
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-4080-9/MediaObjects/10549_2016_4080_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-4080-9/MediaObjects/10549_2016_4080_Fig2_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:161
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Wendie D. den Brok
               affiliation:
                     name:BC Cancer Agency
                     address:
                        name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Caroline H. Speers
               affiliation:
                     name:BC Cancer Agency
                     address:
                        name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lovedeep Gondara
               affiliation:
                     name:BC Cancer Agency
                     address:
                        name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Emily Baxter
               affiliation:
                     name:BC Cancer Agency
                     address:
                        name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Scott K. Tyldesley
               affiliation:
                     name:BC Cancer Agency
                     address:
                        name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Caroline A. Lohrisch
               affiliation:
                     name:BC Cancer Agency
                     address:
                        name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
      description:We hypothesized different Overall Survival (OS) in metastatic breast cancer (MBC) after relapse vs de novo presentation. We identified women in British Columbia with MBC diagnosed between 01/2001 and 12/2009. OS from MBC was calculated for relapsed vs de novo cohorts in 3 subgroups, based on hormone receptors (HR) and HER2 status. Age at MBC, disease-free interval (DFI), de novo vs relapsed, year of MBC diagnosis, and systemic treatment were entered into univariable and multivariable analyses. We identified 3645 pts with known HR of which 2796 had known HER2. Median follow-up was 91 months. Median OS was longer for de novo vs relapsed MBC: HR+/HER2- 34 versus 23 months (mos) (p < 0.0001), HR−/HER2- (TN) 11 versus 8 mos (p = 0.02), HER2+ 29 versus 15 mos (p < 0.0001). For TN disease, no variable independently discriminated a group with increased risk of death. For both the HR +/HER2- and the HER2 + groups, relapsed vs de novo status (HzR 1.4 [95% CI 1.2–1.5; p < 0.0001], and HzR 1.6 [95% CI 1.4–1.9; p < 0.0001], respectively) and age >50 (HzR 1.2 [95% CI 1.1–1.4; p = 0.001] and HzR 1.3 [95% CI 1.1–1.5; p = 0.01], respectively) were associated with increased risk of death on multivariable analysis. These data provide information that may guide discussions about prognosis between physicians and patients with MBC. In addition, it highlights the importance of stratifying for initial stage at diagnosis in future MBC therapeutic trials.
      datePublished:2016-12-20T00:00:00Z
      dateModified:2016-12-20T00:00:00Z
      pageStart:549
      pageEnd:556
      sameAs:https://doi.org/10.1007/s10549-016-4080-9
      keywords:
         Relapsed metastatic breast cancer
         De novo metastatic breast cancer
         Overall survival metastatic breast cancer
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-4080-9/MediaObjects/10549_2016_4080_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-4080-9/MediaObjects/10549_2016_4080_Fig2_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:161
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Wendie D. den Brok
            affiliation:
                  name:BC Cancer Agency
                  address:
                     name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Caroline H. Speers
            affiliation:
                  name:BC Cancer Agency
                  address:
                     name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lovedeep Gondara
            affiliation:
                  name:BC Cancer Agency
                  address:
                     name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Emily Baxter
            affiliation:
                  name:BC Cancer Agency
                  address:
                     name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Scott K. Tyldesley
            affiliation:
                  name:BC Cancer Agency
                  address:
                     name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Caroline A. Lohrisch
            affiliation:
                  name:BC Cancer Agency
                  address:
                     name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:161
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:BC Cancer Agency
      address:
         name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
         type:PostalAddress
      name:BC Cancer Agency
      address:
         name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
         type:PostalAddress
      name:BC Cancer Agency
      address:
         name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
         type:PostalAddress
      name:BC Cancer Agency
      address:
         name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
         type:PostalAddress
      name:BC Cancer Agency
      address:
         name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
         type:PostalAddress
      name:BC Cancer Agency
      address:
         name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Wendie D. den Brok
      affiliation:
            name:BC Cancer Agency
            address:
               name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Caroline H. Speers
      affiliation:
            name:BC Cancer Agency
            address:
               name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Lovedeep Gondara
      affiliation:
            name:BC Cancer Agency
            address:
               name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Emily Baxter
      affiliation:
            name:BC Cancer Agency
            address:
               name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Scott K. Tyldesley
      affiliation:
            name:BC Cancer Agency
            address:
               name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Caroline A. Lohrisch
      affiliation:
            name:BC Cancer Agency
            address:
               name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
      name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
      name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
      name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
      name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
      name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(117)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

6.33s.

LINK . SPRINGER . COM {}